Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Australian Clinical Labs Ltd has announced a change in the interests of a substantial holder, Regal Funds Management Pty Ltd and its associates, in the company’s voting securities. This change reflects a shift in the voting power held by Regal Funds Management, which could impact the company’s governance and decision-making processes, potentially influencing its strategic direction and stakeholder interests.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare sector, providing pathology services across Australia. The company focuses on delivering diagnostic services to medical professionals and patients, contributing to the healthcare system with a wide range of testing services.
Average Trading Volume: 971,985
Technical Sentiment Signal: Sell
Current Market Cap: A$546M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.